KORU Medical Systems Presents Data at Partnership Opportunities in Drug Delivery (PODD) Conference Demonstrating Nursing Preference for Use of KORU FreedomEdge® Infusion System over Manual Syringe Administration for Subcutaneous Oncology Infusion
StockNews.AI · 536 days
High Materiality8/10
AI Summary
97% of nurses prefer KORU FreedomEdge® over manual syringes for oncology infusions. Subcutaneous drug formulation is growing, simplifying treatment and enhancing patient care. 81% of nurses reported less discomfort using KORU system compared to manual methods. KORU plans FDA filing for oncology biologic clearance in 2025. Study shows increased patient interaction time and ease of use with KORU system.
Sentiment Rationale
Nurse preference and FDA filing signal strong market potential for KRMD.
Trading Thesis
Potential FDA clearances and growing subcutaneous drug trend benefit KRMD's future growth.
Market-Moving
- 97% of nurses prefer KORU FreedomEdge® over manual syringes for oncology infusions.
- Subcutaneous drug formulation is growing, simplifying treatment and enhancing patient care.
- 81% of nurses reported less discomfort using KORU system compared to manual methods.
Key Facts
- 97% of nurses prefer KORU FreedomEdge® over manual syringes for oncology infusions.
- Subcutaneous drug formulation is growing, simplifying treatment and enhancing patient care.
- 81% of nurses reported less discomfort using KORU system compared to manual methods.
- KORU plans FDA filing for oncology biologic clearance in 2025.
- Study shows increased patient interaction time and ease of use with KORU system.
Companies Mentioned
- KORU (KORU)
- KRMD (KRMD)
- IV drug manufacturers (IV drug manufacturers)
Industry News
The article highlights significant user preference and upcoming regulatory plans affecting KRMD's growth.